PROXY Laboratories (PROXY) has announced the acquisition of MicroSafe Services (Leiden, the Netherlands), from Merck Millipore, the life science division of Merck, Darmstadt, Germany.
MicroSafe is a microbiological contract laboratory that delivers a complete range of critical testing and consultancy services for the development and production of (bio) pharmaceuticals. In addition to offering the majority of bacteriology tests it is specialised in mycoplasma testing and in vitro virology testing.
Under the agreement, existing MicroSafe customers will have a seamless transition and uninterrupted service with PROXY’s takeover. The MicroSafe employees will be employed by PROXY. No other terms were disclosed.
Dr Ruud Santing, CEO of PROXY, says, "With this acquisition our portfolio of microbiological tests is significantly strengthened. In combination with our analytical R&D and manufacturing departments we can now offer a broad range of activities in high demand by biotech firms. We are excited to provide continued quality and service to our new customers and also look forward to expanding our offerings to this new customer base."
Merck Millipore stated that the transaction is a good fit and creates a positive future for MicroSafe.